Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose intensity and high dose therapy. Two different concepts

R B Livingston1

  • 1Department of Medicine, University of Washington, Seattle 98195.

Cancer
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016
Same author

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

The pharmacogenomics journal·2013
Same author

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Stimulation of area 13 and skin temperature changes following its ablation.

Federation proceedings·2010
Same author

Ablation of area 13 in primates.

Federation proceedings·2010
Same author

Pathology in suddenly decompressed rats.

Federation proceedings·2010
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

High-dose chemotherapy, defined by dose intensity, shows promise in improving long-term survival for breast cancer patients. Ongoing trials aim to validate these findings for both early and advanced stages.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Dose response describes the relationship between chemotherapy dose and antitumor effect, often implying high peak concentrations.
  • Dose intensity, a more precise term, refers to the amount of drug administered per unit of time (mg/m²/week).
  • High-dose chemotherapy regimens, while intensive, carry risks of morbidity and mortality, often requiring hematopoietic stem cell support.

Purpose of the Study:

  • To evaluate the impact of dose intensity and high-dose chemotherapy on breast cancer treatment outcomes.
  • To explore the potential benefits of high-dose therapy in patients with poor prognosis Stage IV and high-risk Stage II breast cancer.

Main Methods:

  • Review of retrospective analyses and prospective Phase II trials of high-dose chemotherapy in breast cancer.
  • Initiation of randomized trials for Stage IV (poor prognosis) and Stage II (high-risk) breast cancer patients to validate observed outcomes.

Related Experiment Videos

  • Investigation of regimens involving autologous hematopoietic stem cell support.

    • Main Results:

    • Phase II trials suggest high-dose therapy may improve long-term survival (≥2 years) in 15-25% of Stage IV patients and increase recurrence-free rates in Stage II patients.
    • Evidence indicates potential for unmaintained disease-free remission in a subset of Stage IV patients treated with high-dose therapy.
    • Standard therapy has historically shown limited success in achieving long-term remission for poor-prognosis Stage IV breast cancer.

    Conclusions:

    • Dose intensity is a critical factor in breast cancer treatment, with high-dose chemotherapy showing potential benefits.
    • Randomized trials are essential to prospectively validate the efficacy of pulsed high-dose chemotherapy regimens.
    • The risk of tumor cell contamination in stem cell collections for support requires careful consideration.